Treatment of ductal carcinoma in situ (DCIS) varies greatly by region and even by practitioner in the US, according to an analysis of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database.
The good news is that the number of women who received a mastectomy for DCIS decreased from 43% in 1992 to 28% in 1999. But researchers found that while many women received overly aggressive treatment, many others received treatment that wasn't aggressive enough. Overall, almost half (42%) of women undergoing mastectomy received axillary dissection, despite current treatment guidelines for DCIS recommending against it. In addition, almost half the women who received lumpectomy received no radiation therapy, despite treatment guidelines since at least 1993 recommending it.
Of the geographic areas examined, Atlanta had the highest rate of axillary dissection with mastectomy, followed by Iowa and Los Angeles. Hawaii had the highest rate of radiation therapy after breast-conserving therapy, followed by Iowa and Connecticut.
Baxter NN, Virnig BA, Durham SB, et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443-448.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More